CXCR3 and neoplasm: Notably, Cxcr3 blockade interfered with the frequency of splenic engineered T cells that expressed Granzyme B (GzmB) (Fig. 6K-L), paralleling the defect in endogenous GzmB + tumor-specific T cells in Cxcr3−/− mice (Fig. 4K).